Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Japan.
Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine Nippon Medical School, Japan.
Intern Med. 2021 May 1;60(9):1427-1432. doi: 10.2169/internalmedicine.5328-20. Epub 2020 Nov 30.
A 77-year-old man was treated with a DPP-4 inhibitor for type 2 diabetes. Hypoglycemia occurred frequently, and an examination revealed a tumor with a maximum diameter of 140 mm in both lobes of the liver. Western immunoblotting detected a high-molecular-weight form of insulin-like growth factor-II, and non-islet cell tumor hypoglycemia was diagnosed. Although prednisolone 40 mg was started, hypoglycemia continued to occur frequently. Surgical tumor removal was not indicated, so lenvatinib was initiated. Hypoglycemia improved quickly, and the tumor shrank until it had partially disappeared. His condition continued to improve, and he was discharged.
一位 77 岁男性因 2 型糖尿病接受 DPP-4 抑制剂治疗。他经常发生低血糖,检查发现肝脏两叶各有一个最大直径为 140 毫米的肿瘤。Western 免疫印迹检测到一种高分子量的胰岛素样生长因子-II,诊断为非胰岛细胞瘤性低血糖症。尽管开始使用泼尼松龙 40 mg,但低血糖仍频繁发生。由于手术切除肿瘤不适用,因此开始使用仑伐替尼。低血糖迅速改善,肿瘤缩小,直至部分消失。他的病情持续改善,最终出院。